ArticleFrontiers in endocrinology2025
Association between the total bilirubin to prothrombin time ratio index and diabetic retinopathy, nephropathy, peripheral neuropathy, and foot disease: a retrospective study and risk prediction model construction.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the association between the total bilirubin-to-prothrombin time ratio index (TBPTRI) and major chronic complications of type 2 diabetes mellitus (T2DM), including diabetic nephropathy (DN), diabetic retinopathy (DR), diabetic peripheral neuropathy (DPN), and diabetic foot (DF), and to evaluate its predictive value for multiple complications. Methods: This retrospective cross-sectional study analyzed 15,695 hospitalized T2DM patients at the Central Hospital of Shaoyang from January 2019 to December 2024, with 5,117 eligible patients ultimately included. Missing data were handled using multiple imputation by chained equations (MICE). Logistic regression was employed to assess the independent correlation between TBPTRI and various complications, while restricted cubic spline (RCS) analysis was used to evaluate nonlinear relationships. To enhance model stability and robustness, subgroup and sensitivity analyses were conducted. Feature variables were further screened using the Boruta algorithm, LASSO regression, and Random Forest (RF) to construct a TBPTRI-based complication risk prediction model. A nomogram was developed, and model performance was evaluated using receiver operating characteristic (ROC) curve analysis. Results: Multivariate logistic regression revealed that TBPTRI was significantly inversely associated with the risks of diabetic nephropathy (OR = 0.61, 95% CI: 0.48-0.79), retinopathy (OR = 0.53, 95% CI: 0.37-0.76), peripheral neuropathy (OR = 0.82, 95% CI: 0.70-0.95), and foot disease (OR = 0.52, 95% CI: 0.40-0.68) (all P < 0.01). RCS analysis indicated nonlinear relationships between TBPTRI and complication risks in diabetic nephropathy and foot disease (P-nonlinear < 0.05). Subgroup analysis demonstrated that the protective effect of TBPTRI remained relatively stable across populations with different clinical characteristics, with significant interactions observed in patients with hypertension or coronary heart disease (CHD). Furthermore, the nomogram constructed using core variables selected by LASSO regression and RF exhibited strong predictive performance, with area under the curve (AUC) values in the test set of 0.871 for nephropathy, 0.647 for retinopathy, 0.735 for peripheral neuropathy, and 0.855 for foot disease. Conclusion: TBPTRI was inversely associated with major chronic complications of T2DM and demonstrated high predictive value for patients with multiple complications. The TBPTRI-based model exhibited robust performance, supporting its utility in early detection, risk stratification, and precision prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.